Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup company CombineAble.AI, which will speed up the development of therapeutics by addressing challenges associated with antibody design.
CombinAble.AI was formed following an AION Labs startup challenge aimed at developing an AI-based solution for...
Publicly listed Daewoong Pharmaceutical has recently unveiled its AI-driven drug development system, powered by a database of hundreds of millions of pre-processed compounds.
WHAT IT'S ABOUT
Over the past two years, researchers of the Seoul-based pharma giant have sought to solve perennial issues in the development of novel drugs, particularly high cost and low efficiency.
Serving as the...
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci's Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates...
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.
The partnership leverages IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic development.
These...
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.
CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT IT DOES
Vivodyne is a drug discovery company that uses clinically predictive AI to help identify therapeutic targets and predict a patient's response to a drug by...
California-based AI drug discovery startup Genesis announced it scored a whopping $200 million in an oversubscribed Series B funding round, bringing its total raise to $280 million.
The company also announced that approximately $24 million of SAFE notes from a prior funding round were converted amid the closing of the Series B round.
Andreessen Horowitz and a "U.S.-based life sciences-focused...
Causaly, a tech company using AI to interpret large datasets and literature, announced it closed a $60 million Series B round led by ICONIQ Growth.
Marathon Venture Capital, Index Ventures, Pentech Ventures, EBRD and Visionaries Club also participated in the round, as did former chairman and CEO of Johnson & Johnson Alex Gorsky and CEO and cofounder of Datadog Olivier Pomel.
WHAT IT DOES...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of its second startup, DenovAI.
DenovAI will develop an AI-enabled computational biophysics platform that can discover potential antibodies directed toward specific epitopes (the part of an antigen molecule recognized by the immune system to which an antibody attaches...
Dozee scores 510(k) for AI contactless sensor for RPM
Indian medical device company Dozee has received the United States Food and Drug Administration's 510(k) clearance for its proprietary contactless sensor for remote patient monitoring.
The Dozee sensor sheet, which is placed under a hospital bed mattress, captures micro-vibrations from patients using Ballistocardiography. These vibrations are...
Ayurveda tech startup NirogStreet snaps up $12M in Series B funding
NirogStreet, an Ayurveda technology platform in India, has scored $12 million in a Series B funding round led by Jungle Ventures.
It provides a community for Ayurveda doctors and an e-commerce platform that streamlines the supply chain of Ayurvedic services and medicine. NirogStreet has onboarded around 50,000 medical...
